Yoshimi JOKO, Kumiko OHKUBO, Toshihiro TANAKA, Yoichiro YOSHIDA, Hiroyuki INOUE, Teppei YAMADA,Hiroshi, MATSUZAKI, Masamitsu KURAKAZU, Makoto HAMASAKI, Kazuki NABESHIMA, et al. Current Status and Efforts of Cancer Genomic Medicine at Fukuoka University Hospital: As the Cancer Genomic Medicine Coordinator. Med. Bull. Fukuoka Univ. 2022. 49. 2. 107-113
Kohjiro Mashino, Maki Tanaka, Miki Yamaguchi, Reiki Nishimura, Yutaka Yamamoto, Hiroaki Ueo, Toshihiro Tanaka, Kenichiro Koga, Tomoyuki Yoshiyama, Shoshu Mitsuyama, et al. Longitudinal efficacy and safety of capecitabine and cyclophosphamide as early-line treatment in patients with metastatic breast cancer: A prospective cohort study by the Kyushu Breast Cancer Study Group, Japan. Annals of Cancer Research and Therapy. 2022. 30. 1. 38-44
Toshihiro Tanaka, Rika Sakai, Ilseung Choi, Junichi Tsukada, Hidenori Sasaki, Yoshiko Naito, Fumiaki Kiyomi, Yasushi Takamatsu, Kazuo Tamura. Comprehensive geriatric assessment as a useful tool in predicting adverse events in elderly patients with diffuse large B-cell lymphoma. Scientific Reports. 2022. 12. 1
Shigeto Maeda, Keisei Anan, Kenichiro Koga, Sayaka Kuba, Hiroshi Yano, Yuichiro Kai, Reiki Nishimura, Uhi Toh, Miki Yamaguchi, Kohjiro Mashino, et al. Baseline neutrophil-to-lymphocyte ratio and absolute lymphocyte count in patients with HER2-negative breast cancer treated with eribulin may predict overall survival. Journal of Clinical Oncology. 2021. 39. 15_suppl. e13005-e13005
Reiki Nishimura, Uhi Toh, Maki Tanaka, Michiyo Saimura, Yasuhiro Okumura, Tsuyoshi Saito, Toshihiro Tanaka, Megumi Teraoka, Kazuo Shimada, Kazuhisa Katayama, et al. Correlation between HER2 related biomarkers (HER2, p95HER2, HER3, PTEN and PIK3CA) and treatment outcome of lapatinib plus capecitabine in HER2-positive metastatic breast cancer refractory to trastuzumab. JOURNAL OF CLINICAL ONCOLOGY. 2016. 34. 15
Yoichiro Yoshida, Masayasu Naito, Teppei Yamada, Naoya Aisu, Daibo Kojima, Toshiyuki Mera, Syu Tanimura, Toshihiro Tanaka, Keiko Naitoh, Kosei Yasumoto, et al. Clinical study on medical value of adoptive immunotherapy with chemotherapy for stage IV colorectal cancer (COMVI study). JOURNAL OF CLINICAL ONCOLOGY. 2016. 34. 4
Current State and Satisfaction Surveys for User of Cancer Consultation Support Center at Fukuoka University Hospital.
(第19回日本臨床腫瘍学会学術集会 2022)
Baseline neutrophil-to-lymphocyte ratio and absolute lymphocyte count in patients with HER2-negative breast cancer treated with eribulin may predict overall survival.
(2021 ASCO Annual Meeting)